Vincristine Sulfate: Brands, Price & Uses in Bangladesh

Vincristine Sulfate is a vinca alkaloid chemotherapy agent used, almost always as part of combination chemotherapy regimens, in the treatment of the following:

Established/FDA-approved uses

• Acute lymphoblastic leukemia (ALL) - in combination with other antileukemic agents
• Hodgkin lymphoma - as part of combination regimens
• Non-Hodgkin lymphomas - as part of combination regimens
• Rhabdomyosarcoma - in combination therapy
• Neuroblastoma - in combination therapy
• Wilms' tumor (nephroblastoma) - in combination therapy

Guideline-supported / commonly used off-label

• Other acute leukemias, multiple myeloma, and certain other solid tumors as part of protocol-based combination chemotherapy, per national and international oncology treatment guidelines
• Idiopathic thrombocytopenic purpura (ITP) refractory to first-line therapy - occasionally used off-label

Vincristine Sulfate is never used as monotherapy for these malignancies; it is always given as one component of a multi-drug chemotherapy protocol under the direction of a qualified oncologist.

Important administration precautions

Vincristine Sulfate must be administered only by a physician experienced in cancer chemotherapy, strictly by the intravenous route. It must never be given intrathecally, intramuscularly, or subcutaneously. It is typically diluted and given via a free-flowing IV line (minibag infusion or slow IV push over 1 minute), with extreme care to avoid extravasation, which can cause severe tissue necrosis.

Exact dose, frequency, and duration are determined by the specific combination chemotherapy protocol, patient response, and toxicity (particularly neurotoxicity and hematologic parameters), and must be individualized by the treating oncologist. Vincristine Sulfate is never self-administered.

Side effects of Vincristine Sulfate are common and dose-related. The most frequent is alopecia (hair loss).

Neurologic (dose-limiting)

• Peripheral sensory neuropathy (numbness, tingling, paresthesia)
• Neuropathic/neuritic pain
• Motor weakness, difficulty walking, foot drop
• Loss of deep tendon reflexes
• Autonomic neuropathy - constipation, paralytic ileus, urinary retention
• Cranial nerve palsies (less common)
• Seizures (rare, sometimes with hyponatremia)

Gastrointestinal

• Constipation, abdominal pain, paralytic ileus (may mimic a surgical abdomen)
• Nausea, vomiting

Hematologic

• Myelosuppression (leukopenia, less pronounced than with many other cytotoxics but still clinically significant)

Local/Other

• Severe tissue necrosis, cellulitis, or phlebitis if extravasation occurs (vesicant)
• Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
• Hyperuricemia/tumor lysis syndrome (particularly at treatment initiation in leukemia/lymphoma)
• Jaw pain
• Rare hepatic veno-occlusive disease, potentially fatal
• Rare hypersensitivity reactions